Home Featured 2

Featured 2

Featured posts

Random

U.S. Drug Approvals: 2010 – 2020

lungcanc

Lung Cancer Global Mortality Projections Skyrocket for Women

Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations to Clinical Practice

Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC

A Cloud-Based Computerized System for the Korean Lung Cancer Screening Project

Milestones in Lung Cancer Treatment

lungcanc

Q&A with Lead ALCHEMIST Investigator, Dr. Ramaswamy Govindan

lungcanc

A Cloud-Based Computerized System for the Korean Lung Cancer Screening Project

lungcanc

Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations...

lungcanc

The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry...

lungcanc

Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?

lungcanc

PACIFIC Flooded Us with Optimism. Now What?

lungcanc

U.S. Drug Approvals: 2010 – 2020

lungcanc

Sustained Funding Vital for Smoking-Cessation Efforts

lungcanc

Déjà Vu, With a Twist: The Vaping Industry’s Approach to Youth-Oriented...

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib